Individualized screening interval for prostate cancer based on prostate-specific antigen level: Results of a prospective, randomized, population-based study

Archives of Internal Medicine

Volumn 165, Issue 16, 2005, Pages 1857-1861

  Aus, Gunnar ^a   Damber, Jan Erik ^a   Khatami, Ali ^a   Lilja, Hans ^b,c   Stranne, Johan ^a   Hugosson, Jonas ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 25144500004     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.165.16.1857     Document Type: Article

References (16)

1. Schröder FH. Screening for prostate cancer. Urol Clin North Am. 2003;30:239-251.
2. US Preventive Services Task Force. Recommendations and rationale: screening for prostate cancer. Available at: http://www.ahrq.gov/clinic/uspstf/ uspsprca.htm. Accessed January 20, 2005.
3. Carter HB. Rationale for earlier and less frequent prostate cancer screening. Urology. 2001;58:639-641.
4. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostatespecific antigen for detection of prostatic cancer. JAMA. 1995;273:289-294.
5. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411-416.
6. Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50-66 years: implications for sampling order. Eur Urol. 2001;39:655-660.
7. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100:1397-1405.
8. Ito K, Yamamoto T, Ohi M, et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less. Prostate. 2003;57:8-13.
9. Crawford D, Chia D, Andriole GL, et al. PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial [abstract]. J Urol. 2002;167(suppl 4):99-100.
10. Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng/ml or less. J Urol. 1997;157:1740-1743.
11. Yamamoto T, Ito K, Ohi M, et al. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/ml or less. Urology. 2001;58:994-998.
12. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. J Urol. 1999;161:835-839.
13. Vis AN, Hoedemaeker RF, Robool M, van der Kwast TH, Schroder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA values (0.0-3.9 ng/ml). Prostate. 2001;47:252-261.
14. Norberg M, Egevad L, Holmberg L, Sparen P, Norlén BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50:562-566.
15. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.
16. Carter HB, Epstein IJ, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable cancer. JAMA. 1997;277:1456-1460.